The LYCRA Company Launches LYCRA EnviroFit™ Fiber at INDEX™ 23
13.4.2023 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the personal care and apparel industries, is exhibiting its newest fiber innovations for hygiene and personal care products at INDEX™ 23, the world’s leading nonwovens exhibition, which takes place at Palexpo in Geneva, Switzerland, April 18 – 21.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005005/en/
The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber for personal care products at INDEX™ 23, April 18 – 21. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping to conserve resources without compromising product performance. (Photo: Business Wire)
At the trade show, The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber, one of the many fibers that the company has developed as part of its Planet Agenda sustainability platform. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping conserve resources without compromising product performance.
“We are thrilled to introduce LYCRA EnviroFit™ fiber, which reduces fiber weight while maintaining the overall quality and performance that personal care products require,” said Scott Blackadar, president, personal care at The LYCRA Company. “Having less mass means fewer resources and less energy are consumed during diaper production. This fiber will appeal to manufacturers who want to significantly reduce their product’s environmental impact and help improve its carbon footprint.”
In addition to continuously improving its range of fibers for personal care products, The LYCRA Company also focuses on providing total solutions for the challenges its customers face. The company is offering two unique delivery technologies aimed at improving the spandex unwinding process and improving diaper line productivity that will also be promoted at the show.
Introducing Trio Loop Yarn Control
The LYCRA Company is showcasing the Trio Loop Technology at INDEX™ 23, the latest yarn control system from BTSR International S.p.A. Trio Loop Technology, in combination with MATRIXCUBE tension controlled plug-and-play unwinding systems, improves yarn tension control and adds more troubleshooting options to further improve diaper line productivity.
Distributing Knotter Type 093E
The LYCRA Company is also the exclusive global distributor of the new and improved Knotter Type 093E for diaper production. This breakthrough innovation by Mesdan S.p.A. offers manufacturers greater efficiency and reliability by eliminating manual knot tying and reducing machine stops.
“By offering these delivery technologies, we are demonstrating that we are a trusted and highly valued solution provider in the industry,” said Werner Hopstaken, global director, personal care at The LYCRA Company. “We are excited to offer our personal care customers these innovative products by BTSR and Mesdan and encourage them to contact us to learn more.”
Visit The LYCRA Company representatives at INDEX™ 23 stand number 2151 or visit this website to discover more benefits of these innovations.
About INDEX™ 23
INDEX™ 23 is the largest global trade show for the nonwovens market. Held every three years, it attracts thousands of visitors from over 100 countries in every region. In addition to its exhibit space, INDEX™ hosts free industry workshops, seminars, tutorials, and presentations during the show. For more information, visit indexnonwovens.com.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, marketing support, and LYCRA ONE™ marketplace. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA EnviroFit™ is a trademark of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005005/en/
Contact information
Werner Hopstaken
werner.hopstaken@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom